Scandion Oncology A/S

Headquarters: Copenhagen, Denmark

Employees: 15

CEO: Dr. Bo Rode Hansen

show_chart OMX: SCOL -1.16%

Market Cap

kr74.6 Million

SEK as of July 1, 2023

US$6.9 Million

history Market Cap History

Scandion Oncology A/S market capitalization over time

Evolution of Scandion Oncology A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Scandion Oncology A/S

Detailed Description

Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.


Unlock the Power of Financial AI:

Try Disfold AI Free for 7 Days!

Stocks & Indices

Scandion Oncology A/S has the following listings and related stock indices.

Stock: OMX: SCOL wb_incandescent




Fruebjergvej 3

Copenhagen, 2100


Phone: 45 38 10 20 17